Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Marketwired
223 Leser
Artikel bewerten:
(0)

Helix BioPharma Corp. Announces Voting Results From Annual and Special Meeting of Shareholders

RICHMOND HILL, ONTARIO -- (Marketwired) -- 12/12/17 -- Helix BioPharma Corp. (TSX: HPB)(FRANKFURT: HBP) ("Helix"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of shareholders held on December 12, 2017 (the "Meeting").

There were 32 shareholders represented in person or by proxy at the Meeting holding 52,631,016 shares, representing 52.60% of Helix's total issued and outstanding shares.

1. Amendment to Articles

The special resolution to amend the articles of Helix to decrease the minimum number of directors of the corporation to four was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the special resolution present or represented by proxy at the Meeting. Management received proxies in respect of the amendment to the articles of Helix as follows:

----------------------------------------------------------------------------
               Votes For                           Votes Against
----------------------------------------------------------------------------
         #                  %                  #                  %
----------------------------------------------------------------------------
     52,501,856           99.97              15,687             0.03%
----------------------------------------------------------------------------

2. Fixing the Number of Directors

The resolution to approve the fixing of the number of directors to be elected at four was approved by a majority of votes cast by shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Management received proxies in respect of fixing the number of directors at four as follows:

----------------------------------------------------------------------------
               Votes For                           Votes Against
----------------------------------------------------------------------------
         #                  %                  #                  %
----------------------------------------------------------------------------
     52,500,856           99.97              16,687             0.03%
----------------------------------------------------------------------------

3. Election of Directors

Each of the nominees for election as directors listed in Helix's management information circular dated November 6, 2017 was elected as a director of Helix for the ensuing year or until their successors are elected or appointed. Management received proxies in respect of the election of directors of Helix as follows:

----------------------------------------------------------------------------
                                    Votes For            Votes Withheld
----------------------------------------------------------------------------
                                       #           %           #           %
----------------------------------------------------------------------------
Sylwester Cacek               52,498,506       99.96      19,037        0.04
----------------------------------------------------------------------------
Heman Chao                    52,499,306       99.97      18,237        0.03
----------------------------------------------------------------------------
Slawomir Majewski             52,499,306       99.97      18,237        0.03
----------------------------------------------------------------------------
Marek Orlowski                52.499,306       99.97      18,237        0.03
----------------------------------------------------------------------------

4. Appointment of Auditor

BDO Canada LLP, Chartered Professional Accountants, was appointed auditor of Helix until the next annual meeting of shareholders at remuneration to be fixed by the directors. Management received proxies in respect of the appointment of the auditor of Helix as follows:

----------------------------------------------------------------------------
               Votes For                          Votes Withheld
----------------------------------------------------------------------------
         #                  %                  #                  %
----------------------------------------------------------------------------
     52,537,839           100.00               10                0.00
----------------------------------------------------------------------------

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Contacts:
INVESTOR RELATIONS
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
905-841-2300
ir@helixbiopharma.com

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 Marketwired
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.